IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression

Nikki A Ford1, Nomeli P Nunez1, Valerie B Holcomb1 and Stephen D Hursting1,2

1Department of Nutritional Sciences, Dell Pediatric Research Institute, University of Texas, 1400 Barbara Jordan Boulevard, DPRI 2.834, Austin, Texas 78722, USA
2Department of Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park, Smithville, Texas 78957, USA

Abstract

Luminal breast tumors with little or no estrogen receptor α expression confer poor prognosis. Using the Met1 murine model of luminal breast cancer, we characterized the IGF1-dependency of diet-induced obesity (DIO) and calorie restriction (CR) effects on tumor growth, growth factor signaling, epithelial-to-mesenchymal transition (EMT), and chemokine expression. Liver-specific IGF1-deficient (LID) and littermate control (LC) mice were administered control, DIO, or 30% CR diets for 3 months before orthotopic injection of Met1 cells. Tumors grew for 1 month and then were assessed for Akt pathway activation and mRNA expression of chemokine and EMT constituents. LID mice, regardless of diet, displayed reduced Met1 tumor growth and downregulated Akt, EMT, and chemokine pathways. CR, relative to control, reduced serum IGF1 and Met1 tumor growth in LC (but not LID) mice. DIO, relative to control, increased Met1 tumor growth and chemokine expression in LID mice, and had no effect on serum IGF1 or pAkt or cyclin D1 expression in either genotype. Thus, circulating IGF1 (in association with Akt, EMT, and chemokines) regulated Met1 tumor growth. While the anticancer effects of CR were largely IGF1-dependent, the procancer effects of DIO manifested only when circulating IGF1 levels were low. Thus, in a murine model of luminal breast cancer, IGF1 and its downstream signaling pathway, EMT, and chemokines present possible mechanistic regulatory targets. Transplanted MMTV1 Wnt1 mammary tumor growth was also reduced in LID mice, relative to LC mice, suggesting that the IGF1 effects on mammary tumor growth are not limited to Met1 tumors.

Key Words

- energy balance
- epithelial-to-mesenchymal transition
- IGF1
- chemokine
- calorie restriction

Endocrine-Related Cancer
(2013) 20, 39–51

http://www.erc.endocrinology-journals.org/
DOI: 10.1530/ERC-12-0329
© 2013 Society for Endocrinology
Printed in Great Britain
Published by Bioscientifica Ltd.

Downloaded from Bioscientifica.com at 02/04/2022 03:48:58AM via free access
Introduction

The prevalence of obesity, an established risk and progression factor for estrogen receptor α (ERα)-positive luminal A breast cancer, has dramatically increased in the USA and many other parts of the world over the past 25 years (Bianchini et al. 2002, Wu et al. 2003). Little is known, however, about the effects of obesity or energy balance modulation on progression of luminal breast tumors with little or no ERα expression (referred to hereafter as ERα<low>), which relative to luminal A tumors confer a worse prognosis, typically respond poorly to tamoxifen treatment, and display activation of growth factor signaling pathways (Loi et al. 2009). The identification of mechanistic targets and intervention strategies for preventing or controlling ERα<low> luminal breast cancers are urgently needed due to the lack of targeted therapies for these aggressive breast cancers (Uray & Brown 2011).

Calorie restriction (CR) is a low calorie diet regimen that prevents obesity and decreases progression of mammary and many other tumor types in various animal models (Nunez et al. 2008, Hursting & Berger 2010, Hursting et al. 2010). The effects of dietary energy balance alterations, such as CR and diet-induced obesity (DIO), on ERα<low> luminal breast cancer are poorly characterized, at least in part due to a paucity of relevant animal models of this intrinsic subtype of breast cancer. Comparative oncogenomic studies on human and mouse mammary tumors show that tumors from the polyoma middle-T antigen transgenic mice cluster closely with human luminal B breast tumors and share many of the pathological and molecular hallmarks of human luminal B tumors (Herschkowitz et al. 2007, Fluck & Schaffhausen 2009, Zhu et al. 2011). Furthermore, the Met1 cell line, derived from a spontaneous tumor from a polyoma middle-T antigen transgenic mouse, progressively loses ER and progesterone receptor positivity with tumor progression, therefore providing a rapid and relevant model for studying ERα<low> luminal mammary tumor progression when orthotopically transplanted into syngeneic mice (Lin et al. 2003, Borowsky et al. 2005, Namba et al. 2006, Bonuccelli et al. 2009).

Findings from models of luminal A, basal-like, and Her2-positive rodent mammary tumor models (Nickerson et al. 1999, Wu et al. 2003, Dunlap et al. 2012), as well as from a broad spectrum of colon, prostate, pancreatic, skin, and other epithelial cancer models (Moore et al. 2008b, Olivo-Marston et al. 2009, Lashinger et al. 2011), indicate that circulating levels of insulin-like growth factor 1 (IGF1) are central to the dietary energy balance-cancer link. Limited evidence suggests plausible relationships between serum IGF1 levels, tumor Akt signaling, tumor expression of epithelial-to-mesenchymal transition (EMT) and chemokine genes, and mammary tumor progression (Kim et al. 2007, Graham et al. 2008, Sivakumar et al. 2009, Lorenzatti et al. 2011, Walsh & Damjanovski 2011). Alterations in systemic IGF1 can modulate cellular signaling through receptor tyrosine kinases and induce changes in downstream proliferation and survival regulators such as Akt and the mammalian target of rapamycin (mTOR; Moore et al. 2008a). Akt and mTOR signaling pathway components are frequently altered in human cancers (Fresno Vara et al. 2004) and are upregulated by DIO and downregulated by CR in mammary and other tumors (Moore et al. 2008a, De Angel et al. 2012). Akt activation can induce EMT (Nath et al. 2008), while Akt inhibitors can suppress EMT (Hong et al. 2009). Characteristics of EMT, an orchestrated program in which cell–cell and cell–extracellular matrix interactions are altered to enhance tumor progression and initiate local invasion and metastasis (Thiery 2003), include the progressive loss of epithelial markers, such as E-cadherin, and gain of mesenchymal markers, such as snail, slug, vimentin, N-cadherin, twist, transforming growth factor B1 (Tgfb1), and matrix metalloproteinases (Mmps) (Rucklidge et al. 1994). Increased body adiposity (Calabro & Yeh 2007, Subbaramaiah et al. 2011) and tumoral Akt activation (Balkwill 1998, 2004, Roca et al. 2008) are also associated with increased tumoral chemokine expression. Chemokines, which are a subfamily of secreted cytokines from adipocytes, macrophages, and other cells that stimulate directed chemotaxis in nearby responsive cells, increase inflammation, tumor progression, and invasion in multiple tumor types (Balkwill 2004, Kulbe et al. 2004, Szlosarek & Balkwill 2004).

Modulation of dietary fat content has been demonstrated to be effective in regulating ER negative breast cancers (Chlebowski et al. 2006), and IGF1 inhibitors are efficacious against triple negative breast cancer cells (Litzenburger et al. 2011). Unfortunately, the effects of energy balance and/or IGF1 modulation on ERα<low> luminal mammary tumor progression are poorly understood. The purpose of this study was to test the hypothesis that DIO enhances, and CR suppresses, ERα<low> luminal mammary tumor progression, at least in part, through IGF1-dependent pathways. To test this hypothesis, we compared the effects of DIO and CR on progression of orthotopically transplanted Met1 tumors, systemic IGF1
(and other serum hormones), tumoral Akt activation, and EMT and chemokine gene expression in mice without genetic reduction of circulating IGF1.

Materials and methods

Mice

All procedures involving animals were approved and monitored by the National Cancer Institute Institute Animal Care and Use Committee or the University of Texas Institutional Animal Care and Use Committee. All diets were purchased from Research Diets, Inc. (New Brunswick, NJ, USA). Liver-specific IGF1-deficient (loxP/+/Cre+/−; LID) mice (Yakar et al. 1999), backcrossed to FVB/N mice for greater than ten generations, were originally obtained from Dr Derek LeRoith (NIDDK, Bethesda, MD, USA), and maintained in Dr Hursting’s breeding colony at the NCI-Frederick National Laboratory (Frederick, MD, USA) or his colony at the University of Texas, Austin (for the Wnt1 study). For these studies, female LID mice and floxed IGF1 littermate control (loxP+/+Cre−/−; LC) mice were obtained at 3 months of age and were placed on a control diet (modified AIN-76A, #D12450B) for 1 week following receipt. Mice were individually housed with free access to water and exposed to a 12 h light:12 h darkness cycle.

Diet treatments and Met1 tumor transplantation, monitoring, and sample collection

Female LID and LC mice were randomized (n = 10/group) to receive: i) control diet fed ad libitum (#D12450B), ii) a 30% CR regimen (#D0302702), or iii) a DIO regimen fed ad libitum (#D12492). The CR diet was balanced so that all essential nutrients would be consumed at the control level when dietary intake was restricted by 30% relative to controls. Food intake was measured biweekly and body weights were recorded weekly. Mice consumed the experimental diets for 3 months before syngeneic orthotopic transplantation of 1×10^5 Met1 mammary tumor cells into the fourth mammary fat pad. The Met1 cell line (a gift from Dr William Mueller) was originally derived from mammary carcinomas in FVB/N-Tg (MMTV-PyVmT) mice (Borowsky et al. 2005), and was maintained in complete media (low glucose DMEM, supplemented with 10% fetal bovine serum, penicillin-streptomycin and glutamine) at 37 °C in a humidified 5% CO2 incubator. In preparation for transplantation, cells were washed with PBS, trypsinized, and viable cells were quantified by trypsin blue exclusion using a hemacytometer (Fisher Scientific, Waltham, MA, USA).

Mice continued to consume the experimental diets for another month after transplantation and before euthanasia. Tumors were measured in three dimensions using electronic calipers twice weekly by one technician, and tumor volume (4/3πlw^3) was calculated. At the end of the treatment period, mice were fasted for 12 h and then anesthetized using isoflurane. Blood was collected by cardiac puncture and the mice were then killed by cervical dislocation. Blood was allowed to coagulate at room temperature for 30 min and then centrifuged at 10 000 g for 5 min to obtain serum samples that were stored at −80 °C until analyzed for hormones and adipokines. Ex vivo caliper measurements of mammary tumors were taken (by the same technician) before tumor tissue was snap frozen in liquid nitrogen and stored at −80 °C until analyzed for protein and/or gene expression.

Serum hormones and adipokines

Serum leptin, insulin, and adiponectin concentrations (n = 10/group) from Met1 tumor bearing mice were measured using a Luminex-based LINCOplex bead array assay (Millipore, Billerica, MA, USA) on a Bio-Rad BioPlex multianalyte detection system (Bio-Rad, Inc.). Serum IGF1 (n = 10/group) was measured using an ELISA (R&D Systems, Minneapolis, MN, USA) on a Synergy 2 plate reader (BioTek, Winooski, VT, USA).

Phosphorylated protein expression analyses

Met1 mammary tumor tissue was homogenized and lysed in a radioimmunoprecipitation assay buffer (Sigma-Aldrich) with a protease inhibitor cocktail tablet (Roche Applied Sciences) and phosphatase inhibitor cocktails I and II (Sigma-Aldrich). Expression of phosphorylated (p) Akt (Ser473), pErk (Thr185/Tyr187), and pStat3 (Tyr705) proteins was quantified on tumor lysates (20 μg) from a random sample of six mice per diet-genotype group, using Luminex-based Milliplex Map bead array assays (Millipore) on a Bio-Rad BioPlex multianalyte detection system following manufacturer’s instructions.

Gene expression analyses

RNA was extracted from Met1 mammary tumor tissue from random samplings of each diet-genotype group (n = 6 mice/sampling) using an RNeasy Mini Kit (Qiagen) as per manufacturer’s instructions. cDNA was synthesized from extracted RNA using the high-capacity cDNA RT Kit (Applied Biosystems) with the addition of an RNase
inhibitor (Ambion) as per manufacturer’s directions. Gene expression for cyclin D1, a panel of EMT markers, and a panel of chemokines was measured by real-time quantitative reverse transcriptase PCR (qRT-PCR) using the TaqMan gene expression assay with TaqMan universal PCR mastermix (Applied Biosystems) on an EPRgradient S Realplex 4 thermocycler (Eppendorf, Hauppauge, NY, USA). Gene expression is reported for LID mice relative to LC mice. In addition, an inflammatory gene superarray analysis was performed in duplicate for 176 inflammation-related genes on a random subsampling of extracted tumor RNA from three LID DIO mice and three LID control diet-fed mice, using an ABI 7900HT FAST qPCR thermocycler (Applied Biosystems). Gene expression is reported relative to LID control.

**MMTV-Wnt1 tumor transplantation, monitoring, and sample collection**

Female LID and LC mice (same as described above; n=10/group) were obtained at 3 months of age from Dr Hursting’s colony at the University of Texas, Austin. Mice were individually housed with free access to water and exposed to a 12 h light:12 h darkness cycle and allowed to acclimate for 1 week before syngeneic orthotopic transplantation of Wnt1 mammary tumor brei, as previously described (Nunez et al. 2008). In brief, a suspension of MMTV-Wnt1 mammary tumor cells was derived (Varticovski et al. 2007) from six spontaneously developed mammary carcinomas in MMTV-Wnt1 FVB/NJ (002934; Jackson Laboratory, Bar Harbor, ME, USA, http://www.jax.org). MMTV-Wnt1 FVB/NJ mice were euthanized with CO2, and tumors were collected aseptically using sterile forceps. Tumors were measured in three dimensions using electronic calipers twice weekly by one technician, and tumor volume (4/3πlwh) was calculated. At the end of the 4-week period after tumor transplantation, mice were fasted for 12 h and then anesthetized using isoflurane. Blood was collected by cardiac puncture and the mice were then killed by cervical dislocation. Blood was allowed to coagulate at room temperature for 30 min and then centrifuged at 10 000 g for 5 min to obtain serum samples that were stored at −80 °C until analyzed for hormones and adipokines. Ex vivo caliper measurements of mammary tumors were recorded.

**Statistical analysis**

Summarized data are expressed as means±s.d., and analyses were performed using SAS 9.2 (Cary, NC, USA). Molecular analysis could not be performed on all LID

Table 1  Diet and genotype affect body weight and serum hormone levels.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Littermate control</th>
<th>DIO</th>
<th>Control</th>
<th>CR</th>
<th>DIO</th>
<th>Control</th>
<th>CR</th>
<th>Genotype</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final body weight (g)</td>
<td>31.2±1.98b</td>
<td>24.4±0.44a</td>
<td>17.6±0.30c</td>
<td>23.1±0.87b</td>
<td>20.6±1.23a</td>
<td>18.3±0.37c</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy intake (kcal)</td>
<td>90.7±5.33b</td>
<td>73.6±2.33a</td>
<td>51.5±1.63c</td>
<td>85.7±2.40a</td>
<td>79.2±4.58b</td>
<td>55.4±3.20b</td>
<td>0.61</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IGF1 (pg/ml)</td>
<td>534±74.1a</td>
<td>507±57.5a</td>
<td>332±22.8b</td>
<td>106.2±12.8a</td>
<td>110±42.3a</td>
<td>71.7±6.66b</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin (pg/ml)</td>
<td>870±183b</td>
<td>552±21.5a</td>
<td>398±13.6b</td>
<td>1750±229a</td>
<td>1880±195a</td>
<td>1610±318a</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptin (pg/ml)</td>
<td>2900±961b</td>
<td>846±175a</td>
<td>358±89.4a</td>
<td>4450±1390a</td>
<td>3630±487a</td>
<td>947±88.8b</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>57.0±9.02a</td>
<td>46.7±5.79a</td>
<td>53.1±8.05a</td>
<td>78.3±10.1b</td>
<td>130±9.12a</td>
<td>98.3±11.1b</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptin:adiponectin</td>
<td>0.06±0.03b</td>
<td>0.02±0.01a</td>
<td>0.01±0.01c</td>
<td>0.07±0.05b</td>
<td>0.03±0.01a</td>
<td>0.01±0.01c</td>
<td>0.25</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Serum was collected at the conclusion of the study from all experimental groups. All serum parameters, excluding IGF1 (R&D Systems, Minneapolis, MN, USA), were analyzed by Millipore multiplex kits (n=10, plated in triplicate). Data represent mean±s.d. values. ANOVA followed by Tukey’s post hoc analysis was used to distinguish statistical differences and considered significantly different when P<0.05 as indicated by different letters. No significant interactions were detected.
tumors due to the size of the tumor at excision; therefore samples were randomly selected from all other groups for analysis. Met1 tumor growth was analyzed by repeated measures ANOVA. Body weight, feed intake, serum adipokines, tumor volume, protein expression, and mRNA gene expression were analyzed by two-way ANOVA followed by Tukey’s post hoc test. When significant interactions were detected, analysis of simple effects was completed. Differences in relative gene expression using the super array were considered biologically significant when a minimum of a twofold expression difference occurred, and $P \leq 0.05$ was achieved. A priori questions addressing the effects of diet on each genotype independently were analyzed by one-way ANOVA followed by Tukey’s post hoc analysis. Final MMTV-Wnt1 tumor volume was assessed by Student’s $t$-test. Differences were considered statistically significant at $P \leq 0.05$.

**Results**

**Body weight, energy intake, and serum hormone levels from Met1 tumor bearing mice**

Final body weights and serum hormone levels after 4 weeks of tumor growth (4 months of diet treatment) and average weekly energy intake throughout the study were analyzed for effects of genotype and/or diet (Table 1). LID mice weighed less than LC mice on DIO or control diet ($P < 0.01$), and LID and LC mice showed the same rank order in weight in response to the three dietary interventions (CR < control < DIO; $P < 0.01$ within each genotype). By design, total caloric intake also significantly varied by dietary group ($P < 0.01$) in the same rank order as weight, and genotype had no effect.

Circulating IGF1 levels were lower in LID mice relative to LC mice, regardless of diet ($P < 0.01$). In both LID and LC mice, CR reduced IGF1 levels ($P < 0.01$), but DIO had no significant effect, relative to control. CR and DIO were significantly different from each other in both LID and LC mice ($P < 0.01$ in both).

Serum concentrations of insulin, leptin, and adiponectin were elevated ($P < 0.01$ each) in LID mice as compared with LC mice (Table 1). Relative to control, CR decreased and DIO increased insulin and leptin levels in LC mice; in LID mice, CR decreased ($P < 0.01$), but DIO had no significant effect on leptin, and neither diet affected insulin levels. While no diet effect on adiponectin was observed in LC mice, CR and DIO (relative to control) both decreased adiponectin in LID mice ($P = 0.02$). Lastly, relative to control, CR reduced, and DIO increased, the ratio of leptin to adiponectin in both genotypes ($P < 0.01$ for both).

**Met1 mammary tumor volume**

Met1 tumor volume at 3 weeks and study completion was significantly lower in LID mice relative to LC mice, regardless of diet ($P < 0.01$) in the same rank order as weight, and genotype had no effect.

![Figure 1](https://via-free-access.com)
irrespective of diet (P<0.01; Fig. 1). Regarding diet effects, in LC mice, relative to control, CR significantly reduced (P=0.01), but DIO had no effect, on final mammary tumor volume. In LID mice, DIO increased final tumor volume (P<0.01), but CR had no significant effect, relative to control. After only 4 weeks of tumor growth, macroscopic Met1 metastases were undetectable in lung or liver tissue.

Cell signaling proteins in Met1 tumor tissue

Phosphorylated tumoral levels of Akt (Fig. 2A) and other signaling molecules in response to dietary energy balance interventions were compared between LID and LC mice. Tumors from LID mice had significantly reduced expression of pAkt relative to tumors from LC mice (P<0.05). No significant diet effect was found for either genotype (LC, P=0.68; LID, P=0.14). Expression of pErk(Thr185/Tyr187) and pSTAT3(Tyr705) in tumor tissue was not modulated by diet or genotype (data not shown).

Cyclin D1, EMT, and cytokine gene expression in Met1 tumor tissue

The mRNA expression of cyclin D1 and several EMT-related genes was significantly altered in LID mice as compared with LC mice. Specifically, relative mRNA expression of cyclin D1 (Fig. 2B), a key downstream target of pAkt, mirrored the relative pAkt protein expression (Fig. 2A) in terms of diet and genotype effects. For EMT genes (Fig. 3), relative to expression in LC tumors, the expression of Mmp2 (P<0.01), which is responsible for matrix degradation, was downregulated in LID tumors, as were Stat3, Cdh2, Fn1, Vim, Snai1 and Twist1 (P<0.01). In contrast, the epithelial marker, E-cadherin was upregulated in LID mouse tumors (P=0.01). There were no differences between LID and LC mice in mRNA expression of the EMT-related genes Snai2, Zeb1, Foxc2, or Pou5f1 (data not shown).

The dietary regimens significantly impacted the expression of EMT markers in mammary tumor tissue from LC, but not LID mice, with the exception of E-cadherin (Fig. 3). In LC mice (but not LID mice), and relative to control, DIO upregulated the expression of Mmp9, twist, Tgfβ1, and vimentin (P<0.03 for each). The expression of the epithelial marker, E-cadherin, was downregulated by DIO, compared with control, in both LC and LID mice (each P<0.01). In LID mice (but not LC mice), and relative to control, CR upregulated E-cadherin expression (P<0.01). CR had no significant effects on other EMT genes in either LC or LID mice. Neither DIO nor CR altered the mRNA expression of the EMT-related genes Snai1 (Fig. 3), Cdh2 (Fig. 3), Snai2, Zeb1, Foxc2, or Pou5f1 (data not shown) in LC or LID mice.

In mammary tissue from LID mice, inflammatory marker marker mRNA superarray analysis identified 17 significantly upregulated genes in response to DIO relative to control diet (Table 2). All changes in gene expression were confirmed by qRT-PCR. The majority (10/17) of the modulated genes was chemokine ligands (n=9) or receptor (n=1), and the expression of these ten genes was further evaluated in tumors from LC and LID mice in response to the dietary regimens (Fig. 4). The expression of
Ccl1, Ccl3, Ccl4, Ccl5, Ccl17, Cxcl2, Cxcl9, and Ccr5, but not Cxcl5, was significantly reduced in tumors from LID mice relative to LC mice (P < 0.03 for each). In LID mice, DIO, compared with control, increased the tumoral expression of each of these genes, and for several of them, to levels near that in LC mice. Tumoral chemokine expression was not significantly affected by DIO or CR in LC mice, or by CR in LID mice.

Figure 3
mRNA expression of epithelial-to-mesenchymal transition (EMT) genes. Relative expression was measured by qRT-PCR using the TaqMan primer/probe system. Gene expression is standardized to β-actin and results are normalized to the expression levels of littermate control mice that consumed control diets. Bars represent mean ± S.D. values (n = 6/group).

Data are analyzed by two-way ANOVA followed by Tukey’s post hoc analysis and considered statistically different when P < 0.05. Significant dietary effects relative to the respective genotype control are indicated by an asterisk and the effect of the LID genotype relative to littermate control is indicated by a bar with asterisk.
MMTV-Wnt1 mammary tumor
The effects of genetically reduced IGF1 levels were also assessed in a model of basal-like ERα low breast cancer. As observed in the Met1 study, in LID mice relative to LC mice serum IGF1 was 70% lower, while insulin and leptin levels were significantly elevated (data not shown). After 4 weeks of tumor growth, Wnt1 tumors in LID mice on control diet were 57% smaller than tumors in LC mice on control diet (P<0.01; Fig. 5). By comparison, Met1 tumors were 95% smaller in LID mice on control diet relative to LC mice on control diet (P<0.01; Fig. 1).

Discussion
In this study, we characterized the effects of dietary energy balance interventions (CR and DIO) on Met1 mammary tumor growth, growth factor signaling, and expression of EMT and chemokine genes in LID and LC mice. We found that i) IGF1 is a critical component modulating Met1 tumor growth, Akt activation, EMT, and chemokine gene expression, regardless of diet; ii) in conditions of low circulating IGF1, the effects of CR on tumor growth are repressed; and iii) DIO increases tumor growth only when circulating IGF1 levels are low and potentially by elevating expression of chemokines. Our results implicate components of the IGF1/Akt, EMT, and chemokine pathways as primary targets for reducing ERα-low luminal mammary tumor growth. In addition, the impact of reduced IGF1 levels on tumor growth was similar in transplanted MMTV-Wnt1 mammary tumors (a model of ERα low basal-like breast cancer), suggesting these findings may have relevance beyond the Met1 mammary tumor model.

Circulating IGF1 levels affect tumor growth in a variety of animal models. Reduced circulating levels of IGF1 in LID mice, relative to LC mice, suppress development of carcinogen-induced skin and colon tumors (Moore et al. 2008b, Olivo-Marston et al. 2009) and growth of transplanted colon and pancreatic adenocarcinomas (Wu et al. 2002, Lashinger et al. 2011). Reduced circulating levels of IGF1 also decrease development of mammary tumors induced either by exposure to the carcinogen 7,12-dimethylbenz (a)anthracene (DMBA) or by crossing LID mice with C3(1)/SV40 large T-antigen transgenic mice, a model of basal-like triple-negative breast cancer (Wu et al. 2003, Herschkowitz et al. 2007, Zhu et al. 2011). Here we further demonstrate that reduced circulating levels of IGF1 also decrease tumor growth in orthotopically transplanted ERα-low Met1 luminal-type mammary tumors and Wnt1 basal-like mammary tumors. The current study is the first, to our knowledge, to show that reduction in circulating IGF1 levels (either genetically or by CR), despite elevated circulating levels of insulin, decreases ERα-low luminal mammary tumor growth. We also demonstrate in the Met1 ERα-low luminal B breast cancer model that, despite enhanced serum insulin levels, reduced circulating levels of IGF1 decrease Akt signaling (pAkt and cyclin D1) and EMT and chemokine gene expression, all of which regulate tumor growth, progression, and/or metastatic potential in other cancer models (Ahmad et al. 1999, Mira et al. 1999, 2001, Akewatchai et al. 2005, Singh et al. 2009, Wu et al. 2010, Durfort et al. 2012).

Pharmacological inhibitors of the IGF1 pathway effectively diminish breast tumor growth in several preclinical models of breast cancer (Maloney et al. 2003, Haluska et al. 2006, Gualberto & Pollak 2009, Sabbatini et al. 2009, Sun et al. 2011). Unfortunately, clinical application has been limited by safety concerns (Gualberto & Pollak 2009) and efficacy due to high phosphorylation of IGF1/insulin receptors in all breast cancer subtypes (Law et al. 2008). Consequently, identifying effective targeted or complimentary interventions with fewer side effects could prove valuable. Our findings suggest that CR (in LC mice) partially mimics liver IGF1 deficiency on Met1 tumor growth, systemic IGF1 levels, tumoral Akt pathway signaling, and EMT and chemokine gene expression. In addition, the inhibitory effects of CR on tumor growth are repressed in LID mice, which provide further evidence that the anticancer effects of CR (at least

### Table 2 RNA superarray analysis identified upregulation of 17 genes in response to DIO relative to control fed LID mice (n=3/group).

<table>
<thead>
<tr>
<th>Gene</th>
<th>Fold change</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL1</td>
<td>9.9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CCL3</td>
<td>2.5</td>
<td>0.04</td>
</tr>
<tr>
<td>CCL4</td>
<td>2.4</td>
<td>0.04</td>
</tr>
<tr>
<td>CCL5</td>
<td>3.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CCL6</td>
<td>2.4</td>
<td>0.02</td>
</tr>
<tr>
<td>CCL17</td>
<td>2.1</td>
<td>0.04</td>
</tr>
<tr>
<td>CXCL2</td>
<td>2.8</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CXCL5</td>
<td>2.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CXCL9</td>
<td>3.7</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>CCR5</td>
<td>2.2</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Itgb2</td>
<td>2.0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Ltb</td>
<td>2.7</td>
<td>0.02</td>
</tr>
<tr>
<td>Il2rb</td>
<td>2.3</td>
<td>0.04</td>
</tr>
<tr>
<td>Il2rg</td>
<td>2.1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Vegfa</td>
<td>2.6</td>
<td>0.02</td>
</tr>
<tr>
<td>Cd40lg</td>
<td>4.4</td>
<td>0.04</td>
</tr>
<tr>
<td>Bmp7</td>
<td>2.3</td>
<td>0.02</td>
</tr>
</tbody>
</table>

DOI: 10.1530/ERC-12-0329 Printed in Great Britain
Published by Bioscientifica Ltd.
Downloaded from Bioscientifica.com at 02/04/2022 03:48:58AM via free access
Figure 4
mRNA expression of chemokine ligands is reduced in Met-1fvb2 tumor tissue of LID mice but expression levels are rescued by the DIO regimen as measured by qRT-PCR using the TaqMan primer/probe system. Bars represent mean ± S.D. values (n = 6/group). Data were analyzed by two-way ANOVA followed by Tukey’s post hoc analysis. P < 0.05 considered statistically significant. Differences by diet (relative to control in respective genotype) indicated by an asterisk and differences by genotype denoted by a bar with an asterisk.
Endocrine-Related Cancer

Effect of circulating IGF1 on Wnt1 murine mammary tumor growth in
littermate control and low-fat (LD) diet deficient (LID) mice. Transplanted
tumors were allowed to grow for 4 weeks and measured biweekly
by electronic calipers (n=10). Data are presented as means±S.D.

DOI: 10.1530/ERC-12-0329 Printed in Great Britain

http://www.erc.endocrinology-journals.org/

Figure 5

Figure 5

Mammary tumors have higher IGF1 levels on the DIO diet than FVB mice,
which spontaneous tumor development and serum IGF1
elevations induced by hyperphagia are consistent with previous findings in MMTV-neu transgenic mice (a model
of an ER-β-HeR2-overexpressing luminal breast cancer). In
MMTV-Wnt1 mammary tumors, DIO increases tumor growth (Dogan
et al. 2007, Nunez et al. 2008, Gu et al. 2008). Thus, additional
studies are needed to fully discern whether the lack of
response of the FVB host mice to DIO. We observed a
modest enhancing effect of DIO (associated with increased
chemokine gene expression in mammary cancer). Two recent
in vivo studies using sera from db/db mice
and media from adipocyte cultures (Kushiro & Nunez 2011, Kushiro et al. 2011) as well as a recent report of an in vivo
study using MMTV-Wnt1 mice (Dunlap et al. 2012) suggest
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
and ARCoP prostate cancer cells, and that, in contrast,
limited evidence suggests that activation of the IGF1 pathway promotes invasive-
downstream target cyclin D1. Limited evidence suggests
that increased adiposity promotes EMT. This is consistent
with our observation that several EMT markers are
increased in tumors from LC mice in response to DIO,
changes, and tissue architecture remodeling (Lee et al. 2000). Additionally, increased proliferation of human breast cancer cells (MDA231) is associated with increased expression of Tgfβ (Tobin et al. 2002), while increased angiogenesis in MCF7 mammary tumor cells is associated with increased expression of Twist (Mironchik et al. 2005). A limitation of this study is the lack of macroscopic metastasis to lung or liver tissue which may be attributed to the short duration of tumor growth (4 weeks). Future studies are needed to further establish the links between energy balance, IGF1, and EMT in Erβlow luminal mammary tumor progression and metastasis. Because tumors from Lid mice display increased E-cadherin expression and decreased expression of several other EMT-related genes regardless of diet, a novel association between IGf1 and EMT in a model of Erβlow luminal B breast cancer is suggested that warrants further investigation.

In conclusion, in a murine model of Erβlow luminal B breast cancer, circulating IGF1, in association with tumoral Akt, EMT, and chemokine signaling, regulates tumor growth. Also while the anticancer effects of CR, at least in part, are IGF1-dependent, the procancer effects of DIO associated with enhanced chemokine expression manifest only when circulating IGF1 levels are low. Thus, components of the IGF1/Akt, EMT, and chemokine pathways represent possible mechanistic targets for inhibiting Erβlow luminal breast cancer.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the Breast Cancer Research Foundation (UTA09-001068; S D Hursting), the NIEHS Center for Research on Environmental Disease (17183/88015573; S D Hursting), and an American Institute for Cancer Research Postdoctoral Fellowship (N A Ford).

Author contribution statement
N A Ford, N P Nunez, and S D Hursting contributed to study design and interpretation of data, and wrote the manuscript. N A Ford also conducted the wet lab analyses for the Met1 study. V B Holcomb conducted the MMTV-Wnt1 study.

Acknowledgements
The authors thank Dr Susan N Perkins for assistance with study design, Mark A Smith for assistance with data analysis, and Faye Geigerman for assistance with serum hormone and tumor phosphorylated protein analysis.

References


Nunez NP, Perkins SN, Smith NC, Bennigan D, Berendes DM, Varticovski L, Barrett JC & Hursting SD 2008 Obesity accelerates mouse mammary


